Of the 20 trial participants, only two patients to-date have...

Of the 20 trial participants, only two patients to-date have received an initial dosing, which took place in December
2022 (refer ASX release 7 December 2022).

All of the data prepared in this release are from a total of two patients. I have not attained a PhD in biostatistics (please chip in if you have), but a barely-commenced clinical study where n=2 is a curious basis for a 5 page press release from a public company.

The 'Disclosure Committee' want to show off how well their trial is going, for obvious reasons. Not convinced disclosures like this will restore investor confidence or sp.